金城医药(300233.SZ)：子公司收到药品GMP符合性检查告知书

Core Viewpoint - Jincheng Pharmaceutical's subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received the GMP compliance inspection notice for the active pharmaceutical ingredient Mirabegron, allowing for domestic production and sales [1] Group 1: Company Developments - The approval from the Beijing Drug Administration signifies that the Mirabegron active pharmaceutical ingredient has passed the GMP compliance inspection, which is based on the 2010 revised Drug Production Quality Management Standards [1] - This achievement enhances the variety of products offered by the company and is expected to improve its competitiveness in the chemical raw material drug sector [1] - Jincheng Tail will proceed with production in accordance with relevant requirements and market demand [1]